This dual enzymatic and epigenetic inhibition synergistically reduces tumor-associated PGE2 by 90% in melanoma xenografts, attenuating PGE2-driven VEGF secretion and CD31+ tumor vasculature density [30]. Here, VEGFA is linked to melanoma.